Objective: Cardiovascular complications are still the main cause of death in longterm transplant recipients. Left ventricular hypertrophy (LVH) and increased aortic stiffness -reflected by elevated pulse pressure (PP) -are predictors of cardiac death in patients with end-stage renal disease (ESRD). We evaluated the PP and LVH development, furthermore the association between calcineurininhibitor treatment (CNI), PP and LVH in ESRD and after transplantation.
Hypertension prevalence increases with advancing age, accompanied by increasing arterial stiffness. Whether comparable vascular changes occur in normotensive individuals with aging is not known.
We examined blood pressure (BP, oscillometric), heart rate (HR) and hemodynamic parameters (stroke volume SV, cardiac output CO, systemic vascular resistance SVR, by thoracic bioimpedance) by age decade in 640 normal subjects evaluated as renal donors. Those with hypertension (Ͼ140/90 mmHg or antihypertensive medication), renovascular or renal disease were excluded. Mean age was 41Ϯ 1 years (range 18-72), with 256 males, 384 females. Systolic and diastolic BP rose with age. CO declined, mediated by lower SV while HR was unchanged. SVR increased progressively with age. Trends were similar when hemodynamic measurements were indexed to body surface area. Absolute impedance rose with age as did impedance change with posture. While BP and CO were lower and HR and SVR higher in women compared to men, hemodynamic changes with age occurred in parallel. Once indexed to BSA, CO and SVR measures did not differ by gender even though BP was lower in women.
Our results indicate a prevailing age-related rise in vascular tone mediates higher BP with advancing age in association with normal to low cardiopulmonary volume. As CO falls, BP rise is mediated by accentuated systemic vasoconstriction. This may result in declining perfusion to multiple vascular beds including the kidney, accounting for the decline in glomerular filtration rate seen with aging via reduced renal blood flow. Hypertension(HBP), hypertensive heart disease and left ventricular (LV) hypertrophy are integral to symptomatic diastolic heart failure. Tissue inhibitor of metalloproteinase 1 (TIMP-1) is linked to extracellular matrix fibrosis and is elevated in HBP. We explored the link between circulating TIMP-1, matrix metalloproteinase 9 (MMP-9) and resting echocardiographic LV filling.
Circulating MMP-9 and TIMP-1 levels were measured in citrated plasma by ELISA in 74 patients with HBP (58 male, age 58 Ϯ 11yrs) and 34 controls (23 male, age 53Ϯ 13years) with normal systolic function.
There were significant differences in many of the parameters reflecting diastolic dysfunction, and both MMP-9 and TIMP-1 were higher in the hypertensive group (Table) . Within the hypertensive cohort, only TIMP-1 correlated with left ventricular mass index (rϭ0.323,pϭ0.007) and tissue Doppler parameters of diastolic dysfunction (e'(rϭϪ0.338,pϭ0.005), a' (rϭϪ0.350, pϭ0.005) and e/e'(rϭ0.334,pϭ0.005).
TIMP-1 is thought to increase tissue concentrations of collagen type I by preventing its breakdown by matrix metalloproteinases. Our findings therefore add weight to a hypothesis suggesting that TIMP-1 may be a key mediator of left ventricular diastolic dysfunction through definition of the ventricular matrix composition. 
